Holen Sie sich die Stockscreener-App
223.12
1.31%
-2.96
Handel nachbörslich:
223.80
0.68
+0.30%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$226.08
Offen:
$226.08
24-Stunden-Volumen:
4.00M
Relative Volume:
0.68
Marktkapitalisierung:
$394.34B
Einnahmen:
$59.64B
Nettoeinkommen (Verlust:
$2.36B
KGV:
168.35
EPS:
1.3253
Netto-Cashflow:
$19.68B
1W Leistung:
-0.88%
1M Leistung:
+1.81%
6M Leistung:
+17.54%
1J Leistung:
+26.64%
1-Tages-Spanne:
$222.39
$226.12
1-Wochen-Bereich:
$222.39
$230.94
52-Wochen-Spanne:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
223.12 | 399.57B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
997.59 | 904.25B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.62 | 486.51B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
130.17 | 253.59B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
98.93 | 247.51B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
AbbVie (NYSE:ABBV) Shares Down 1.4%Here's Why - MarketBeat
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) - GlobeNewswire Inc.
How Investors May Respond To AbbVie (ABBV) Expanding Its Pipeline With New Migraine And Oncology Data - Yahoo Finance
Why Investors Shouldn't Be Surprised By AbbVie Inc.'s (NYSE:ABBV) Low P/S - 富途牛牛
Ose Immunotherapeutics stock falls after AbbVie deal amendment By Investing.com - Investing.com UK
SVB Wealth LLC Sells 113,330 Shares of AbbVie Inc. $ABBV - MarketBeat
Ossiam Has $51.75 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Gabelli Funds LLC Cuts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Jump Financial LLC Buys New Shares in AbbVie Inc. $ABBV - MarketBeat
OSE Immunotherapeutics Amends Partnership With AbbVie for Inflammation Drug Development - marketscreener.com
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development - Yahoo Finance UK
Ophthalmic Drugs Market Size to Cross USD 62.74 Billion by 2032, Driven by Advances in Eye Care Treatments and Rising Global Vision Disorders - GlobeNewswire Inc.
Federated Hermes Inc. Acquires 134,942 Shares of AbbVie Inc. $ABBV - MarketBeat
California Public Employees Retirement System Sells 778,732 Shares of AbbVie Inc. $ABBV - MarketBeat
Cerity Partners LLC Has $210.15 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Stenger Family Office LLC Takes Position in AbbVie Inc. $ABBV - MarketBeat
SCS Capital Management LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
1832 Asset Management L.P. Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Shares Down 1.1%What's Next? - MarketBeat
Mirabella Financial Services LLP Has $2.41 Million Position in AbbVie Inc. $ABBV - MarketBeat
Marshall Wace LLP Grows Stake in AbbVie Inc. $ABBV - MarketBeat
M Holdings Securities Inc. Increases Holdings in AbbVie Inc. $ABBV - MarketBeat
Quantbot Technologies LP Takes Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Position Lifted by Epoch Investment Partners Inc. - MarketBeat
Amundi Purchases 2,435,372 Shares of AbbVie Inc. $ABBV - MarketBeat
Arrowstreet Capital Limited Partnership Has $58.79 Million Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer - PR Newswire
Is AbbVie Inc. (4AB) stock undervalued after correctionWeekly Trade Summary & Community Consensus Picks - Newser
How Strong Is AbbVie's Immunology Franchise After Humira's LOE? - The Globe and Mail
Could buying AbbVie today set you up for life? - MSN
Could Buying AbbVie Today Set You Up for Life? - Nasdaq
Dry Eye Disease Treatment Market Outlook Report 2032 | Alcon - openPR.com
Kennedy Capital Management LLC Reduces Holdings in AbbVie Inc. $ABBV - MarketBeat
Why AbbVie Inc. stock attracts global investorsMarket Performance Summary & Fast Exit and Entry Strategy Plans - Newser
First Trust Advisors LP Trims Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts - ts2.tech
Baird Financial Group Inc. Sells 36,202 Shares of AbbVie Inc. $ABBV - MarketBeat
Assessing AbbVie’s (ABBV) Valuation After New Cancer Data, EPKINLY Approval, and Dividend Hike - simplywall.st
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Dermal Fillers Market Size Report 2032 | AbbVie Inc., Galderma, - openPR.com
AbbVie looks to expand use cases for migraine drug after promising study - Crain's Chicago Business
Invesco Ltd. Lowers Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by CW Advisors LLC - MarketBeat
Is AbbVie Inc. stock undervalued at current priceSwing Trade & Weekly High Conviction Ideas - Newser
Is It Too Late to Consider AbbVie After Its Strong Multi Year Share Price Rally? - Yahoo Finance
AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook - ts2.tech
Metastatic Non-Small Cell Lung Cancer Market on Track for Major Expansion by 2034, According to DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics - Barchart.com
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73 - simplywall.st
AbbVie to feature new data at ASH 2025 - MarketScreener
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers - Investing News Network
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):